Defence Therapeutics Inc.
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
Transactions
This announcement as a matter of record only
PowerOne acted as Finder in connection with this financing
About
PowerOne provides early stage capital and advisory services to emerging growth companies. Since inception in 2003, PowerOne has assisted private and public companies across an array of sectors globally.
PowerOne is an Exempt Market Dealer and is registered in Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, Nova Scotia and Quebec.
